

JC07 Rec'd PCT/PTO 21 APR 2005
Pct

PTO/SB/21 (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/519,121
	Filing Date	September 15, 2003
	First Named Inventor	Marc K. HELLERSTEIN
	Art Unit	Not Yet Assigned
	Examiner Name	Not Yet Assigned
Total Number of Pages in This Submission	6 + 25 Refs.	Attorney Docket Number 416272003900

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement w/ Form PTO/SB/08a/b (5 pages) <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): 1. One Copy of each 25 Cited References 2. Return Receipt Postcard
<div>Remarks</div>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	MORRISON & FOERSTER LLP (Customer No. 20872) Michael R. Ward - Reg. No. 38,651
Signature	<i>Michael R Ward</i>
Date	April 18, 2005

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.	
Dated: April 19, 2005	Signature: <i>Leah Kjellen</i> (Leah Kjellen)



I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: April 19, 2005

Signature:

(Leah Kjellen)

Patent
Docket No. 416272003900
B02-077

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Marc K. HELLERSTEIN

Serial No.: 10/519,121

Filing Date: September 15, 2003

For: METHODS FOR MEASURING RATES
OF REVERSE CHOLESTEROL
TRANSPORT IN VIVO, AS AN INDEX
OF ANTI-ATHEROGENESIS

Examiner: Not Yet Assigned

Group Art Unit: Not Yet Assigned

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §1.97 and § 1.98, Applicant submits for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of foreign documents and non-patent literature are submitted herewith. The Examiner is requested to make these documents of record.

This Supplemental Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☐ Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
- ☒ **Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.**
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - ☐ A fee is required. A check in the amount of ___ is enclosed.
 - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly, no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of ___ is enclosed.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)


Applicant would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.

The information contained in this Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicant petitions for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petition and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing docket no. **416272003900**.

Dated: April **18**, 2005


Respectfully submitted,

By 

Michael R. Ward

Registration No.: 38,651

MORRISON & FOERSTER LLP
425 Market Street
San Francisco, California 94105-2482
Telephone: (415) 268-6237
Facsimile: (415) 268-7522



Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/519,121
				Filing Date	September 15, 2003
				First Named Inventor	Marc K. HELLERSTEIN
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	416272003900

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	1.	US-4,332,784	06-01-1982	Smith et al.	
	2.	US-5,439,803	08-08-1995	Ross et al.	
	3.	US-6,653,076	11-25-2003	Franza, Jr. et al.	
	4.	US-2003/0148533	08-07-2003	Malloy et al.	
	5.	US-2003/0180710	09-25-2003	Lee et al.	
	6.	US-2003/0180800	09-25-2003	Lee et al.	
	7.	US-2004/0091943	05-13-2004	Schneider	
	8.	US-2004/0152994	08-05-2004	Meier-Augenstein	
	9.	US-2004/0253647	12-16-2004	Mathews et al.	
	10.	US-10/523,250	FD 01-26-2005	Hellerstein	
	11.	US-10/526,860	FD 09-04-2003	Hellerstein	
	12.	US-10/872,280	FD 06-17-2004	Hellerstein	
	13.	US-11/064,197	FD 02-22-2005	Hellerstein	
	14.	US-11/078,083	FD 03-11-2005	Hellerstein	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	15.	WO-90/11371	10-04-1990	Anticancer, Inc.		
	16.	WO-93/25705	12-23-1993	Barranco		
	17.	WO-03/061479-A1	07/31/2003	Hellerstein		
	18.	WO-03/068919-A2	08/21/2003	Hellerstein		
	19.	WO-03/087314-A2	10/23/2003	Hellerstein		
	20.	WO-04/003493-A2	01/08/2004	Hellerstein		
	21.	WO-04/011426-A2	02/05/2004	Hellerstein		
	22.	WO-04/021863-A2	03/18/2004	Hellerstein		
	23.	WO-04/024941-A2	03/25/2004	Hellerstein		
	24.	WO-04/025270-A2	03/25/2004	Hellerstein		
	25.	WO-04/042360-A2	05/21/2004	Hellerstein		
	26.	WO-05/009597-A2	02/03/2005	Hellerstein		
	27.	WO-05/015155-A2	02/17/2005	Hellerstein		

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

sf-1910317

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/519,121
				Filing Date	September 15, 2003
				First Named Inventor	Marc K. HELLERSTEIN
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	416272003900

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	28.	International Search Report mailed on August 20, 2004, for PCT application no. PCT/US03/10554 filed on April 4, 2003, 4 pages		
	29.	International Search Report mailed July 8, 2004, for PCT patent application no. PCT/US03/27623 filed on September 4, 2003, 4 pages		
	30.	International Search Report mailed on March 25, 2005, for PCT application no. PCT/US04/39722 filed on November 24, 2004, 3 pages		
	31.	International Search Report mailed on April 4, 2005, for PCT application no. PCT//US04/21063 filed on June 29, 2004, 2 pages		
	32.	BLACK, G.E. et al. (January 2001) "Labeling DNA with Stable Isotopes: Economical and Practical Considerations," <i>BioTechniques</i> 30:134-140		
	33.	HO, D.D. et al. (1995) "Rapid Turnover of Plasma Virions and CD4 Lymphocytes in HIV-1 Infection," <i>Nature</i> 373:123-126		
	34.	HSIEH, Elaine A. et al. (2004) "Dynamics of Keratinocytes in Vivo Using 2H2O Labeling: A Sensitive Marker of Epidermal Proliferation State," <i>J Invest Dermatol</i> , 123: 530-536		
	35.	MESSMER, Bradley T. et al. (Feb. 10, 2005) "In Vivo Measurements Document the Dynamic Cellular Kinetics of Chronic Lymphocytic Leukemia B Cells," <i>J. Clin. Invest.</i> doi:10.1172/JCI200523409		
	36.	PARK, S. S., et al. (1997) "Measurement of Small Intestinal Cell Turnover with [6,6, 2H2] Glucose," <i>Berkeley Scientific, Abstract</i> 1(2):41-43		
	37.	NEESE, R. A. et al. (Nov. 2002) "Measurement in vivo of Proliferation Rates of Slow Turnover Cells by 2H2O Labeling of the Deoxyribose Moiety of DNA," <i>PNAS</i> , 99(24): 15345-15350		
	38.	SMITH, et al. (1983) "The Phosphogluconate Oxidative Pathway," in <i>Principles of Biochemistry</i> , 7th edition, McGraw-Hill Book Company, pp. 417-423.		
	39.	WOLFE, R. (1990) "Isotopic Measurement of Glucose and Lactate Kinetics," <i>Ann. Med.</i> 22:163-170		

^{*}EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

sf-1910317